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ABSTRACT
Introduction Breast and cervical cancers pose a major 
public health burden globally, with disproportionately 
high incidence, morbidity and mortality in low- and 
middle- income countries (LMICs). The majority of 
women diagnosed with cancer in LMICs present with 
late- stage disease, the treatment of which is often 
costlier and less effective. While interventions to 
improve the timely diagnosis of these cancers are 
increasingly being implemented in LMICs, there is 
uncertainty about their role and effectiveness. The 
aim of this review is to systematically synthesise 
available evidence on the nature and effectiveness of 
interventions for improving timely diagnosis of breast 
and cervical cancers in LMICs.
Methods and analysis A comprehensive search 
of published and relevant grey literature will be 
conducted. The following electronic databases will be 
searched: MEDLINE (via PubMed), Cochrane Library, 
Scopus, CINAHL, Web of Science and the International 
Clinical Trials Registry Platform (ICTRP). Evidence 
will be synthesised in accordance with the Preferred 
Reporting Items for Systematic Review and Meta- 
Analyses (PRISMA). Two reviewers will independently 
screen the search outputs, select studies using 
predefined inclusion criteria and assess each included 
study for risk of bias. If sufficient data are available and 
studies are comparable in terms of interventions and 
outcomes, a meta- analysis will be conducted. Where 
studies are not comparable and a meta- analysis is not 
appropriate, a narrative synthesis of findings will be 
reported.
Ethics and dissemination As this will be a systematic 
review of publicly available data, with no primary 
data collection, it will not require ethical approval. 
Findings will be disseminated widely through a peer- 
reviewed publication and forums such as conferences, 
workshops and community engagement sessions. 
This review will provide a user- friendly evidence 
summary for informing further efforts at developing and 
implementing interventions for addressing delays in 
breast and cervical cancer diagnosis in LMICs.
PROSPERO registration number CRD42020177232.
INTRODUCTION
Breast and cervical cancer constitute a major 
public health burden globally.1 2 They are 
particularly burdensome in low- and middle- 
income countries (LMICs), where their 
incidence, morbidity and mortality are dispro-
portionately high.2 3 Breast cancer, the the 
most common cancer among women world-
wide, accounts for about 30% of all cancers in 
women in LMICs.4 The majority (53%) of new 
breast cancer cases occur in women living in 
LMICs.5 With an age- standardised incidence 
rate (ASIR) of 31 per 100 000 women, there 
are over half a million new cases every year 
in LMICs.4 Cervical cancer represents 16% 
of the total cancer burden in LMICs, with an 
ASIR of 16 per 100 000 women and an inci-
dence of 300 000 new cases every year.2 Nine 
out of every 10 of these cases will likely lead to 
premature death.2
Nearly 70% of all cancer deaths, including 
those due to breast and cervical cancer, 
occur in LMICs.4 Of greater concern is 
that the number of new cancer cases, their 
associated morbidity and deaths in LMICs 
are expected to grow substantially in the 
Strengths and limitations of this study
 ► This protocol was designed in accordance with stan-
dard systematic review protocol guidelines.
 ► Literature search will be comprehensive, covering 
both peer- reviewed and relevant grey literature.
 ► No language restriction will be applied in the search.
 ► It is possible that the review will not include all rele-
vant literature available, as some may not be acces-
sible at the time of review.
 ► The overall strength and applicability of the synthe-
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coming decades.6 This growth will be due in part to 
population growth, shifts in demographics and expo-
sures to known risk factors, in keeping with the epide-
miological transition from communicable diseases to 
non- communicable diseases.1 6 While the incidence 
of cancers increases in LMICs, many cases continue 
to go undiagnosed because of a lack of high- quality 
population- based registries, and when diagnosed, the 
majority present at late- stage with consequently poor 
outcomes.7–9
Breast and cervical cancer mortality and survival are 
largely influenced by the timeliness of diagnosis and 
effectiveness of treatment modalities.7 8 10 In many 
LMICs, breast and cervical screening and early diagnosis 
programmes do exist in some form, however, they tend 
to be opportunistic and not well organised.11–13 There is 
often poor access to high quality, affordable breast and 
cervical cancer treatment, particularly where the health 
systems are fragile or fragmented.6 14 In addition to these 
health system factors are the underlying sociocultural and 
financial barriers to cancer prevention, diagnosis and 
treatment services.6 12 15 16 Lay beliefs, such as beliefs that 
breast cancers are punitive consequences of sins or a type 
of divine retribution, are held within some communi-
ties in LMICs, as are concerns that breast cancer surgery 
may result in deformity, which may subsequently lead to 
divorce or family abandonment.13 17 As a result of these 
issues, women in LMICs with breast and cervical cancers 
may be reluctant to seek care following their awareness of 
symptoms, leading to delays in diagnosis. Consequently, 
a high proportion of patients are diagnosed at advanced 
stage, when treatment is often less effective and more 
expensive.12 15
Evidence suggests that improved timeliness of 
cancer diagnosis is critical for optimising patients’ 
navigation of the pathway from symptom awareness to 
treatment and follow- up.18–20 Timely cancer diagnosis 
can enhance opportunities for treatment with cura-
tive intent.21 However, much of this evidence is from 
high- income countries (HICs), many of which do not 
have the sociocultural, financial, health system and 
knowledge barriers to timely cancer diagnosis and 
effective cancer treatment that many LMICs grapple 
with.6 8 In an effort to address this evidence gap and 
provide global standards for early cancer diagnosis, the 
WHO published the WHO Guide to Cancer Early Diag-
nosis in 2017.22 The guide provides a clear framework 
for cancer control programmes around the world to 
systematically address barriers that may impede timely 
cancer diagnosis, treatment and care. More recently, 
the 2020 WHO report on cancer specifies three steps 
of early cancer diagnosis: awareness of symptoms, 
rapid clinical and pathological diagnosis and referral 
to an appropriate treating facility.23
The distinct phases of cancer patients’ pathways 
from symptom awareness to diagnosis and treatment 
have been described. They include patients’ awareness 
of symptoms; access to clinical evaluation, diagnosis 
and staging; access to treatment; and follow- up.14 18 
The phases are conceptualised based on the Model of 
Pathways to Treatment framework proposed by Walter, 
Scott and colleagues, which identifies five key events 
in the pathway to care: detection of bodily changes; 
perceived reasons to discuss symptoms with a healthcare 
provider; first consultation with a healthcare provider; 
diagnosis and start of treatment.24 25 The framework 
also identifies four important intervals between these 
phases: the appraisal, help seeking, diagnostic and the 
pre- treatment intervals. These events and processes 
represent particular moments at which barriers may 
exist and delay patients’ access to care before or after 
a cancer diagnosis.7 26
STUDY RATIONALE
Interventions aimed at promoting early breast and 
cervical cancer detection are increasingly being 
adopted globally, particularly in HICs.21 27 28 Given 
the substantial differences between HICs and LMICs 
regarding health resources, environment, infrastruc-
ture, technology and medical personnel, improving 
time to diagnosis for breast and cervical cancer in 
LMIC settings may require different approaches.3 
We have identified two previous reviews on this topic 
within the LMIC context.6 8 A scoping review by Dalton 
and colleagues synthesised the evidence on patient 
navigation strategies for cancer care in LMICs, but 
focussed broadly on the entire cancer detection, 
treatment and care continuum, and not specific to 
breast or cervical cancer.6 The literature search was 
concluded in December 2018. A systematic review by 
Qu and colleagues assessed interventions specifically 
aimed at addressing barriers to early cancer diagnosis 
in LMICs.8 However, it did not specifically focus on 
breast and cervical cancer, and the literature search 
was concluded in November 2017.
Therefore, our review aims to provide a more up 
to date, robust and comprehensive synthesis of the 
evidence on the nature and effectiveness of interven-
tions for improving timely diagnosis of breast and 
cervical cancer in LMICs. We have focussed on early 
diagnosis of symptomatic breast and cervical cancers, 
as the outcome (such as clinical downstaging) is easier 
to evaluate, unlike screening in which outcomes may 
be complicated by factors such as the time lag between 
cervical cancer screening and symptom development, 
as well as over- diagnosis of precancerous cervical 
lesions that may not have become symptomatic nor 
pose a serious health threat even without intervention. 
Overall, the review seeks to provide a user- friendly 
evidence summary for health policymakers, cancer 
programme managers, oncologists and early cancer 
diagnosis programme implementers, for informing 
further efforts at addressing breast and cervical cancer 
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The protocol is designed in accordance with the Preferred 
Reporting Items for Systematic Review and Meta- Analysis 
Protocols (PRISMA- P) guidelines.29 The review has been 
registered on the International Prospective Register of 
Systematic Reviews (PROSPERO, registration number: 
CRD42020177232).30
Search strategy
The search strategy will be developed with guidance from 
a health sciences subject librarian, in accordance with the 
Cochrane highly sensitive search guidelines.31 The search 
strategy will be pre- tested prior to the actual search.
Search terms and free- text words will be combined 
using the Boolean operators ‘AND’ and ‘OR’, such as 
(breast OR cervical OR cervix, cancer OR neoplasm OR 
malignancy OR tumours) AND (diagnosis OR diagnostic 
OR screening OR detection OR discovery) AND (early 
OR timely OR time OR late OR delay) AND (efficacy 
OR effectiveness OR improvement). In order to restrict 
search to LMICs, a filter containing all LMICs countries, 
regional blocs and other common categorisations will be 
added. See online supplemental appendix 1 for provi-
sional search strategy.
A comprehensive literature search will be conducted 
on the following electronic databases: MEDLINE (via 
PubMed), Cochrane Library (including the Cochrane 
Central Register of Controlled Trials (CENTRAL) and 
the Database of Abstracts of Reviews of Effects (DARE)), 
Scopus, CINAHL, Web of Science and the International 
Clinical Trials Registry Platform (ICTRP). The literature 
search will be guided by the research question using the 
Population, Intervention, Comparison, Outcome and 
Study design (PICO) strategy.32 Search terms will include 
the use of controlled descriptors (such as MedicalSub-
ject Headings terms, CINAHL and headings) and their 
synonyms. Additionally, relevant grey literature will be 
searched for potentially eligible articles, including the 
publication database of the WHO’s International Agency 
for Research on Cancer (IARC), the Cancer Atlas of the 
Union for International Cancer Control (UICC) and the 
Global Cancer Project Map. A hand- search of reference 
lists of included studies and grey literature sources will be 
conducted to identify additional published and grey liter-
ature. For recency, only articles published over the last 
10 years (from 2010 to date) will be considered eligible. 
No language restrictions will be applied, and any poten-
tially eligible article in a language other than English will 
be translated using a web- based translation tool.33 The 
preliminary literature search was initiated on 22 June 
2020.
Study selection
The study inclusion criteria will be guided by the research 
question: ‘What interventions have been used for 
improving timely diagnosis of breast and cervical cancers 
in LMICs, and how effective are they?’. Our PICO criteria 
in line with the research question are outlined below:
Eligible studies will have to report on early diagnosis 
strategies for breast and cervical cancers targeting women, 
the general public or healthcare workers in LMICs. The 
definition of LMICs will be based on the World Bank’s 
current classification using per capita gross national 
income.34 Multinational literature involving LMIC and 
non- LMIC countries and meeting inclusion criteria will 
be included, except where country- specific information 
cannot be abstracted.
Included articles will be required to involve an inter-
vention or implemented strategy that aimed to influence 
the timeliness of breast or cervical cancer diagnosis, 
whether as a single focus intervention or as multi- focus 
intervention targeting more than one cancer type. 
Studies focussed solely or mainly on the theoretical or 
conceptual knowledge, attitude and perception of the 
timeliness of breast or cervical cancer diagnosis without 
assessing intervention outcomes will be excluded, as will 
those reporting outcomes there are not related to diag-
nostic timeliness. Studies with interventions focussed 
primarily on screening of asymptomatic individuals will 
also be excluded.
Where applicable, articles that compared between 
reported interventions and usual standard of practice 
(without intervention) will be included. Studies that 
compared multiple interventions (such as those targeting 
different populations such as cancer patients, healthcare 
workers or communities) will also be considered. There-
fore, study design eligibility will include randomised trials, 
non- randomised trials and observational studies, with or 
without controls. However, inclusion will be limited to 
primary studies, while systematic and scoping reviews will 
be excluded.
Intervention outcomes will not be limited to any partic-
ular type, in order to capture as many relevant studies as 
possible. These may include improvements in knowledge, 
stage of disease at presentation, reduction in delay from 
symptom awareness to diagnosis, time from health facility 
presentation to definitive diagnosis or time interval from 
receipt of specimen to pathology reporting of final diag-
nosis. Outcomes will be classified according to the essen-
tial steps of early cancer diagnosis as specified in the 
WHO Guide to Cancer Early Diagnosis.22
Screening and data extraction
The review process will consist of two levels of screening: a 
title and abstract screening to identify potentially eligible 
publications and review of full- texts to select those to be 
included in the review based on predefined inclusion/
exclusion criteria. For the first level of screening, two 
reviewers (CAN and PK) will independently screen the 
titles and abstracts of all retrieved records from the search 
output. Articles that are considered relevant by either 
or both of the reviewers will be included in the full- text 
review. Following the removal of duplicates, full texts of 
remaining studies will be retrieved. In the second step, 
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the two reviewers will then independently assess the full 
texts to determine if they meet the inclusion/exclusion 
criteria. Any discordance in their eligibility assessment 
will be resolved through consensus between the two 
researchers. Any further disagreements will be resolved 
by a third reviewer (JM).
Two reviewers (CAN and PK) will independently 
extract and record all relevant data from the included 
articles using a standardised data extraction tool, adapted 
from the framework proposed by Carlos and colleagues.35 
The tool includes four domains: (1) study identification 
details (article title; journal title; authors; country of the 
study; language; publication year; host institution of the 
study); (2) methodological characteristics (study design; 
study objective or research question or hypothesis); 
sample characteristics (eg, sample size; sex; age, ethnicity; 
groups and controls; follow- up duration; validation of 
measures; statistical analyses); (3) main findings, and (4) 
conclusions. Study eligibility will be re- verified at the start 
of/during data extraction.
Where the relevant outcome data in the original article 
are unclear or missing, the corresponding author will be 
contacted via email for clarification. Any disagreements 
between the two reviewers will be resolved by discussion, 
and if a consensus is not reached, a third reviewer (JM) 
will arbitrate. The first reviewer (CAN) will combine the 
two spreadsheets of extracted data for analysis. PK will 
double- check the entered data for completeness and 
verify the accuracy of analysis. JM and FMW will review 
analysed data for accuracy and consistency with protocol.
Study quality assessment
Two reviewers (CAN and PK) will independently assess 
each included study for risk of bias; again, disagree-
ments will be resolved by a third reviewer (JM). For 
randomised trials, the five domains of the Cochrane risk 
of bias tool will be used.36 These five domains include: 
the randomisation process (random sequence generation 
and allocation concealment), deviations from intended 
interventions (blinding of participants and personnel), 
measurement of the outcome (blinding of outcome 
assessment), incomplete outcome or missing data and 
selective outcome reporting. For each included study, 
the two reviewers will independently describe and make 
judgement of ‘Low risk’ of bias, ‘High risk’ of bias or 
‘Some risk’ of bias accordingly.
For non- randomised and observational studies, the 
Risk of Bias In Non- randomised Studies of Interventions 
(ROBINS- I) tool will be used for assessing methodolog-
ical quality.37 The tool covers seven distinct domains: 
confounding; selection; intervention classification; 
deviations from intended interventions; missing data; 
measurement of outcomes and selection of reported 
results. Overall, risks of bias judgements are categorised 
as ‘Low risk’, ‘Moderate risk’, ‘Serious risk’ and ‘Critical 
risk’ of bias, with ‘Low risk’ corresponding to the risk of 
bias in a high quality randomised trial. Both reviewers’ 
independent risk of bias assessments will be compared, 
and any discrepancies will be resolved by discussion and 
consensus. The risk of bias for each outcome across indi-
vidual studies will be summarised as a narrative statement, 
and supported by a risk of bias table presenting domain- 
specific judgements.
Descriptive analysis and meta-analysis
A narrative synthesis of all relevant findings from the 
included studies will be reported in accordance with the 
PRISMA statement.38 A PRISMA flow diagram will be used 
to illustrate the literature search results and study selec-
tion process (see online supplemental appendix 2). If 
sufficient data are available and studies are comparable in 
terms of interventions and outcomes, a meta- analysis will 
also be conducted. In case of moderate- to- high hetero-
geneity between studies (I2 statistic >25%), estimates will 
be pooled using random effect meta- analysis models, 
otherwise fixed effect models will be used.39 A fixed effect 
meta- analysis assumes all studies are estimating the same 
(fixed) treatment effect, whereas a random effects meta- 
analysis allows for differences in the treatment effect 
across studies.40 Where studies are not comparable and 
a meta- analysis is not feasible, only a narrative report of 
findings will be presented. The meta- analysis will present 
outcomes as risk ratios with their corresponding 95% CIs 
for dichotomous data, and standardised mean differences 
(SMD) with their corresponding 95% CIs for continuous 
data. The SMD will be categorised as small, medium and 
large based on the thresholds 0.2, 0.5 and 0.8, respec-
tively, as proposed by Cohen.41 The 95% CI will be used to 
represent the deviation from the point estimate for both 
the individual studies and the pooled estimate.
Heterogeneity between the studies will be assessed 
using Forest plots visually, as well as statistically using 
the χ2 test of homogeneity (with significance defined 
at the 10% α-level and quantified with the Higgins’ I2 
statistic).39 42 Funnel plots of estimated differences in 
outcome effects against their SEs will be used to assess the 
presence of publication bias. Publication bias is defined 
as the tendency of authors to publish studies with signifi-
cant results.43 This will be assessed if at least 10 studies are 
included in the meta- analysis.42 Subgroup analyses will 
be conducted, with subgroups defined by study design, 
cancer site, type of intervention and region/continent.
Sensitivity analyses will be performed to assess the effect 
of risk of bias on pooled estimates, and to investigate the 
robustness of the pooled estimates (ie, by including and 
excluding studies with high risk of bias and/or those that 
did not use validated outcome measurement tools).
The Grades of Recommendation Assessment, Devel-
opment and Evaluation (GRADE) approach will be 
employed to assess the certainty of the evidence on the 
effectiveness of reported interventions.44 This critical 
appraisal of the certainty of each evidence will be useful 
for dealing with, and interpreting conflicting findings. A 
table summarising findings from each included study will 
be presented. Meta- analysis will be performed with the 
Review Manager 5.3 (RevMan) review software.45
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Patient and public involvement
As this will be a review of publicly available literature, 
patients and the public were not directly involved in the 
design of this protocol.
Ethics and dissemination
This will be a systematic review of publicly available liter-
ature, with no primary data collection. Hence, it will not 
require ethical approval. Findings will be disseminated 
widely through peer- reviewed publication and in various 
media, for example, conferences, congresses or symposia: 
This review will provide a user- friendly evidence summary 
for health policymakers, cancer programme managers 
and frontline health workers, for informing further 
efforts at addressing breast and cervical cancer diagnostic 
delays in LMICs, while identifying opportunities for 
future research.
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